The Warehouse Without Cars: Radiopharma’s Investment Paradox

The radiopharmaceutical industry is building factories, securing isotopes, and acquiring pipelines. But what happens if there is nowhere for all of that innovation to go?

Investment across radiopharmaceutical development reflects confidence in the field’s potential. Manufacturing capacity is expanding. Isotope access has become strategically important. New targets, radionuclides, and delivery platforms continue to enter development.

These investments address real constraints. Yet another constraint is becoming increasingly important: clinical capacity.

The industry can manufacture more radiopharmaceuticals and advance more candidates, but those assets still need qualified sites, nuclear medicine infrastructure, trained teams, imaging capabilities, radiation safety programs, and patients who can realistically access treatment.

It is the equivalent of building a warehouse full of cars without enough roads to drive them.

Investment Is Expanding the Front End of the Pipeline

Radiopharmaceutical development has advanced considerably from its earlier diagnostic foundations. Zhang et al. describe more than 60 radiopharmaceuticals approved for diagnosis or treatment and an expanding development landscape involving targets such as FAP, PSMA, SSTR, CXCR4, GRPR, integrins, and others.[1]  

The science is also diversifying across radionuclide classes. Established beta-emitting therapies are being joined in development by alpha emitters including actinium-225, astatine-211, and lead-212.[1] These advances create opportunities to match targeting vectors and radionuclide properties more precisely to disease biology.  

For investors and development teams, manufacturing capacity and isotope supply are therefore rational priorities. Zhang et al. specifically identify production limitations and high costs as challenges for several alpha-emitting radionuclides.[1]  

But solving production does not solve development.

The Infrastructure Gap Moves Downstream

Every additional radiopharmaceutical candidate eventually encounters the same requirement: it has to be studied in patients.

That requires a specialized clinical ecosystem.

Radiopharmaceutical trials depend on coordination across investigators, nuclear medicine, radiopharmacy, imaging, radiation safety, clinical operations, and often dosimetry. Sites must be capable of receiving, handling, administering, and managing radioactive investigational products while meeting protocol and regulatory requirements.

The Theragnostic Insights brand framework identifies site capabilities and requirements, radioactive-material regulations, and practical clinical implementation as distinctive challenges for radiopharmaceutical developers.  

As pipelines multiply, competition for experienced sites can increase. The result is a radioligand therapy infrastructure gap that capital investment alone cannot immediately resolve.

A new manufacturing facility can increase supply. It cannot create an experienced nuclear medicine team at a clinical site overnight.

Theragnostic Insight: Manufacturing capacity determines whether a radiopharmaceutical can be produced. Clinical capacity determines whether it can actually be developed. Investment strategies need to account for both.

Clinical Capacity Is an Asset, Too

This changes how sponsors—and investors evaluating them—should think about infrastructure.

A development plan should extend beyond isotope availability and manufacturing scalability to ask whether the clinical network can support the intended pipeline.

How many qualified sites are realistically available? How many competing radiopharmaceutical studies are targeting those institutions? Can additional community centers be developed? What training, licensing, equipment, and workflows would be required? Can the supply chain reliably reach those sites within radionuclide-specific constraints?

These questions are particularly relevant because radionuclides vary substantially in half-life, production method, radiation characteristics, and clinical application.[1]  

The physical properties of the product therefore shape the infrastructure needed to develop it.

For investors, this means clinical execution deserves consideration during diligence alongside target biology, intellectual property, isotope supply, manufacturing, and regulatory strategy. A scientifically compelling asset can still encounter significant delays if the clinical ecosystem needed to test it is insufficient.

Building Capacity Before It Becomes the Bottleneck

The solution is not simply to push more trials through the same academic centers.

The longer-term opportunity is to expand Theragnostic clinical trial capacity deliberately.

That can include identifying community oncology centers with relevant nuclear medicine capabilities, developing site-readiness frameworks, creating radiopharmaceutical-specific training, designing protocols around real-world workflows, and engaging potential sites earlier in development.

This approach aligns clinical infrastructure investment with pipeline investment.

It also supports something more fundamental: patient access. Concentrating specialized trials within a small number of institutions can create geographic and operational barriers for patients. Building a broader capable site network can help development scale while bringing investigational therapies closer to the populations they are intended to serve.

What This Means for You

Radiopharmaceutical investment is accelerating the field, but the value of those investments ultimately depends on clinical translation.

Factories matter. Isotope supply matters. Pipelines matter.

So does the infrastructure required to treat the first patient, enroll the next one, and execute consistently across every participating site.

For biotech and pharma leaders, clinical capacity should be treated as a strategic development consideration early enough to influence protocol design, site strategy, and operational planning. For investors, the ability to translate scientific and manufacturing assets into executable clinical programs should be part of assessing development readiness.

Theragnostic Insights works at that intersection—connecting radiopharmaceutical science, clinical strategy, site capability, and practical implementation.

Because a growing pipeline needs more than somewhere to be manufactured.

It needs somewhere to go.

References

[1] Zhang S, Wang X, Gao X, et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy, 10:1.  

[2] International Atomic Energy Agency. Nuclear Medicine in Diagnosis and Therapy. IAEA.

[3] U.S. Food and Drug Administration. Oncology Drug Development and Clinical Trial Resources. FDA.

[4] Society of Nuclear Medicine and Molecular Imaging. Radiopharmaceutical Therapy Centers of Excellence Program. SNMMI.

‍